Back to Search
Start Over
Cost-effectiveness of a pediatric dengue vaccine.
- Source :
-
Vaccine [Vaccine] 2004 Mar 12; Vol. 22 (9-10), pp. 1275-80. - Publication Year :
- 2004
-
Abstract
- To ascertain the economic feasibility of a pediatric tetravalent dengue vaccine, we developed and calibrated a cost-effectiveness model of vaccinating children at 15 months in Southeast (SE) Asia using a societal perspective. We assumed that full immunization would require two doses at prices of US$ 0.50 and US$ 10 per dose in the public and private sectors, respectively. The gross cost per 1000 population (of all ages) of the vaccination program would be US$ 154. Due to projected savings in dengue treatment, the net cost per capita would be only US$ 17 (89% below the gross cost). The cost per disability adjusted life year (DALY) saved by a pediatric vaccine would be US$ 50, making the potential vaccine highly cost-effective. Eventually, vaccination may be able to replace environmental control as a strategy for dengue prevention and be cost saving.
Details
- Language :
- English
- ISSN :
- 0264-410X
- Volume :
- 22
- Issue :
- 9-10
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 15003657
- Full Text :
- https://doi.org/10.1016/j.vaccine.2003.09.019